These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

833 related items for PubMed ID: 29881257

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE, Kennedy RD.
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [Abstract] [Full Text] [Related]

  • 3. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN, Monk BJ.
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [Abstract] [Full Text] [Related]

  • 4. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    Nirsimloo R, Gourley C.
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428
    [Abstract] [Full Text] [Related]

  • 5. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ, Walters Haygood CL, Arend RC, Leath CA, Straughn JM.
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [Abstract] [Full Text] [Related]

  • 6. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    Oncotarget; 2017 Jul 18; 8(29):47154-47160. PubMed ID: 28454085
    [Abstract] [Full Text] [Related]

  • 7. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE, Ledermann JA.
    Clin Adv Hematol Oncol; 2016 Sep 18; 14(9):704-11. PubMed ID: 27673289
    [Abstract] [Full Text] [Related]

  • 8. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC, Moore KN.
    Future Oncol; 2015 Sep 18; 11(5):747-57. PubMed ID: 25757679
    [Abstract] [Full Text] [Related]

  • 9. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.
    Lancet Oncol; 2016 Nov 18; 17(11):1579-1589. PubMed ID: 27617661
    [Abstract] [Full Text] [Related]

  • 10. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    Expert Opin Investig Drugs; 2016 Nov 18; 25(5):597-611. PubMed ID: 26899229
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A, Leary A.
    Bull Cancer; 2017 Nov 18; 104(11):971-980. PubMed ID: 29054544
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.
    N Engl J Med; 2018 Dec 27; 379(26):2495-2505. PubMed ID: 30345884
    [Abstract] [Full Text] [Related]

  • 17. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U.
    Lancet Oncol; 2014 Jul 27; 15(8):852-61. PubMed ID: 24882434
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B.
    Gynecol Oncol; 2016 Feb 27; 140(2):199-203. PubMed ID: 26723501
    [Abstract] [Full Text] [Related]

  • 19. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF, Matulonis UA.
    Curr Oncol Rep; 2016 May 27; 18(5):29. PubMed ID: 26984416
    [Abstract] [Full Text] [Related]

  • 20. Olaparib for the treatment of ovarian cancer.
    Bornstein E, Jimeno A.
    Drugs Today (Barc); 2016 Jan 27; 52(1):17-28. PubMed ID: 26937492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.